Gryrotonic Training in Behcet-diseased Elders With Breast Cancer
Breast Cancer · Behcet Disease
What this study involves
The registry says this study is recruiting. Individual locations may have different availability.
- Study type
- Interventional
- Phase
- Not applicable
- Age range
- 65 years - 75 years
- Sex eligible
- Female
- Healthy volunteers
- Not accepted
- Participants
- 40 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
gryrotonic training may be a good exercise modality in Behcet-diseased elders with breast cancer
Read the full description
forty Behcet-diseased elders with breast cancer will randomy divide into group I (receive gyrotonic exercise three session weekly for 12 week) or group II (wait list)
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- beast cancer survivors
- behcet diseas patients
Exclusion Criteria:
- cardiac or repiratory or renal failure patients
Treatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Random assignment
- Masking
- Single masked
group number 1
twenty Behcet-diseased elders who survived from breast cancer will receive gyrotonic exercise three session weekly for 12 week. the session will 45 min
Behavioral: exercise
group number 2
twenty Behcet-diseased elders who survivied from breast cancer will be wait list for 12 weeks
exercise BEHAVIORAL
twnety Behcet-diseased elders who survived from breast cancer will receive gyrotonic exercise three session weekly for 12 week. the session will last for 45 min
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Short Physical Performance Battery
Time frame: it will be measured after 12 weeks
the total score will be calcualted
Secondary measures
Dual task gait speed
Time frame: It will be measured after 12 weeks
this task assess gait speed
Four-square step test
Time frame: It will be measured after 12 weeks
it is fucntional balnce test
grip strenghts
Time frame: It will be measured after 12 weeks
it is a measure of grip strenghths in dominant hand
time up- and go testing
Time frame: It will be measured after 12 weeks
it is a measure of fall risk
sit-to-stand 30-second testing
Time frame: It will be measured after 12 weeks
asess number of repteations of sit-to-staning in 30 seconds
six minute walking testingg
Time frame: It will be measured after 12 weeks
distance covered by subject in six minutes wil be assessed
10-meters walking testing
Time frame: It will be measured after 12 weeks
time covered for walking for ten meter will be assessed
trunk-flexor McGill core endurance test
Time frame: It will be measured after 12 weeks
this test will assess endurance of trunk flexors
trunk-extensor McGill core endurance test
Time frame: It will be measured after 12 weeks
this test will assess endurance of trunk extensors
right-lateral-trunk-bending McGill core endurance test
Time frame: It will be measured after 12 weeks
this test will assess endurance of right lateral trunk bendors
left-lateral-trunk-bending McGill core endurance test
Time frame: It will be measured after 12 weeks
this test will assess endurance of left lateral trunk bendors
arm flexion in thrity seconds
Time frame: It will be measured after 12 weeks
it will assess numbers (repeations) of arm flexion in thirty second
maximal nubmer of push up
Time frame: It will be measured after 12 weeks
this will assess maximal number of performed psh ups in speciifc time
behcet disease quality of life
Time frame: It will be measured after 12 weeks
questioanire that will assess life quality in behcet disease (total score will be estiamted)
total score of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it is a questioaire asess quality of life
physical fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it is a questioaire asess physical fucntion related quality of life
role fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it is a questioaire asess role fucntion related quality of life
emotional fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it is a questioaire asess emotional fucntion related quality of life
cognitive fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it is a questioaire asess cognitive fucntion related quality of life
social fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it is a questioaire asess social fucntion related quality of life
fatigue fucntioning subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it is a questioaire asess fatigue
nausea-vomiting subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it is a questioaire asess nausea-vomiting
pain subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it will assess pain
dyspnea subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it will assess dyspnea
insomnia subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it will assess insomnia
appetite-loss subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it will assess appetite loss
constipation subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it will assess constipation
diarrhea subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it will assess diarrhea
financial difficulties subscale of European-Organization-for-Research and Treatment-of-Cancer Quality-of-Life Questionnaire-Core 30
Time frame: It will be measured after 12 weeks
it will assess financial difficulties
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
Cairo UniversityGiza, Dokki, EgyptRecruiting
Study team and timeline
- Lead sponsor
- Cairo University
- Study start
- Nov 30, 2026 Estimated
- Primary completion
- May 30, 2027 Estimated
- Study completion
- May 30, 2027 Estimated
- First posted
- Nov 10, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
Gryrotonic Training in Behcet-diseased Elders With Breast Cancer
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026